361275
3′-Deoxy-3′-fluorothymidine
97%
Synonym(s):
3′-Fluoro-2′,3′-dideoxythymidine, 3′-Fluorodeoxythymidine
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C10H13FN2O4
CAS Number:
Molecular Weight:
244.22
MDL number:
UNSPSC Code:
41106305
PubChem Substance ID:
NACRES:
NA.22
Pricing and availability is not currently available.
Recommended Products
Quality Level
Assay
97%
form
solid
mp
176-178 °C (lit.)
storage temp.
2-8°C
SMILES string
CC1=CN([C@H]2C[C@H](F)[C@@H](CO)O2)C(=O)NC1=O
InChI
1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1
InChI key
UXCAQJAQSWSNPQ-XLPZGREQSA-N
Gene Information
human ... TK2(7084)
Looking for similar products? Visit Product Comparison Guide
Related Categories
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
P Herdewijn et al.
Journal of medicinal chemistry, 30(8), 1270-1278 (1987-08-01)
A series of 2',3'-unsaturated and 3'-substituted 2',3'-dideoxynucleoside analogues of purines and pyrimidines have been synthesized and evaluated for their inhibitory activity against human immunodeficiency virus (HIV). The 2',3'-unsaturated analogues of 2',3'-dideoxycytidine (ddeCyd) and 2',3'-dideoxythymidine (ddeThd), 3'-azido-2',3'-dideoxythymidine (AzddThd), 3'-fluoro-2',3'-dideoxythymidine, 2',3'-dideoxycytidine (ddCyd)
Julian L Goggi et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(9), 1630-1636 (2013-08-03)
Successful antiangiogenic therapies have been developed for the treatment of various cancers, but not all patients respond. Therefore, the early determination of therapy efficacy is essential for patient management. This study was done to evaluate the utility of various PET
Yuka Yamamoto et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 53(12), 1911-1915 (2012-10-20)
We evaluated 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake in patients with newly diagnosed and recurrent gliomas and correlated the results with tumor grade and proliferative activity. (18)F-FLT PET was investigated retrospectively in 56 patients, including 36 with newly diagnosed gliomas and 20 with
J M Y Willaime et al.
Physics in medicine and biology, 58(2), 187-203 (2012-12-22)
Intra-tumour heterogeneity is a characteristic shared by all cancers. We explored the use of texture variables derived from images of [(18)F]fluorothymidine-positron emission tomography (FLT-PET), thus notionally assessing the heterogeneity of proliferation in individual tumours. Our aims were to study the
Eliot T McKinley et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(3), 424-430 (2013-01-24)
Selective inhibition of oncogenic targets and associated signaling pathways forms the basis of personalized cancer medicine. The clinical success of (V600E)BRAF inhibition in melanoma, coupled with the emergence of acquired resistance, underscores the importance of rigorously validating quantitative biomarkers of
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
